Altiratinib is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a potent inhibitor of multiple kinases, including MET, TIE2, and VEGFR2, which are often implicated in tumor growth, angiogenesis, and metastasis. This makes it particularly effective in combating cancers that rely on these pathways for progression. Its application is being explored in clinical trials for various solid tumors, such as glioblastoma, colorectal cancer, and other malignancies with dysregulated MET signaling. By blocking these key pathways, altiratinib helps to inhibit tumor proliferation, reduce blood vessel formation that feeds tumors, and potentially prevent the spread of cancer cells to other parts of the body. Its targeted approach aims to minimize damage to healthy cells, offering a more precise and potentially less toxic treatment option compared to traditional chemotherapy.